According to medical experts, in Vietnam, chronic kidney disease is an alarming health problem with more than 8.7 million people suffering from the disease, accounting for 12.8% of the population. However, the early detection rate is still very low, with only 4.5-15.5% of patients diagnosed at stage 3. About 800,000 people are in the final stage, requiring dialysis or kidney transplant, with a mortality rate of nearly 50% within 5 years of treatment, creating a huge economic and social burden.
In order to respond effectively, Long Chau Pharmacy has upgraded its strategic cooperation with Boehringer Ingelheim, pioneering the launch of the Early Screening Program for Chronic Kidney Disease in the community. The program focuses specifically on high-risk groups such as patients with chronic diabetes, cardiovascular disease and metabolic disorders, aiming to detect early and minimize dangerous complications.
This is also a campaign to celebrate 10 years of Boehringer Ingelheim's journey to bring new treatment solutions to Vietnam with the message: "Early detection - Timely control of chronic kidney disease, comprehensive protection of the cardiovascular system, kidneys and metabolism - Towards a healthy life".
The highlight of the program is the cooperation between Long Chau Pharmacy, Boehringer Ingelheim and local medical centers in using a rapid urine protein testing device - a modern tool that can help detect early proteinuria, a warning sign of potential kidney disease.
Positive cases will be consulted and guided to perform specialized tests to comprehensively assess kidney function, creating opportunities for early treatment and proactively preventing serious complications. This is an urgent action to help people access information and proactively monitor their health, promptly detect early signs of abnormalities through scientific surveys for early examination before the disease becomes severe.
Long Chau Pharmacy joins forces with Boehringer Ingelheim, Germany's leading pharmaceutical company, to announce the implementation of an early screening program for chronic kidney disease.
With the scale being expanded, this year, the two units will accelerate the implementation of 30 programs in many provinces and cities nationwide. Previously, Long Chau and Boehringer Ingelheim signed a comprehensive strategic cooperation agreement and organized free screening for type 2 diabetes, heart failure, and chronic kidney disease at some Long Chau pharmacies and local health stations.
Ms. Nguyen Do Quyen, Deputy General Director of FPT Retail and Executive Director of FPT Long Chau Pharmacy and Vaccination System, shared that today marks a meaningful milestone when Long Chau and Boehringer Ingelheim jointly launched a nationwide community campaign to detect early chronic kidney disease, especially in diabetic patients - a silent but serious disease that is often overlooked.
At Long Chau Pharmacy, kidney disease is always in the top 10 most prescribed diseases, reflecting the increasing prevalence and need for early intervention and prevention.
Through this program, the two units will coordinate with local health centers across Vietnam, helping thousands of people to perform simple, quick and free proteinuria tests. Most importantly, the community will have the opportunity to receive timely diagnosis and access to early prevention methods.
“With over 2,000 stores nationwide, we believe that providing medicines is just one link in the healthcare journey. The real focus is on proactively connecting, raising awareness and making prevention more accessible.
With a team of 18,000 professionally trained pharmacists, always aware of their mission in the journey of community health care, more than just a pharmacy, we are committed to becoming a bridge to contribute to improving the health care of Vietnamese people. We are proud to accompany Boehringer Ingelheim on this path", Ms. Quyen emphasized.
Empagliflozin is used in adults with type 2 diabetes and existing cardiovascular disease.
Mr. Oliver Koehncke, General Director of Boehringer Ingelheim Vietnam shared: “This series of free early screening programs for chronic kidney disease marks an important step forward in the cooperation journey between Boehringer Ingelheim Vietnam and FPT Long Chau, towards the goal of comprehensive care for cardiovascular - renal - metabolic health for millions of patients. This effort demonstrates our shared belief that healthcare needs to be accessible, proactive and prevention-focused, not just treatment.
In the next stage, Boehringer Ingelheim is committed to continuing to promote research and development of breakthrough solutions in the fields of cardiovascular - renal - metabolic, continuing the mission of improving the lives of many generations in Vietnam," Mr. Oliver added.
Strengthening control, early detection and treatment management play an important role in disease prevention and building a healthy community.
Along with that, Boehringer Ingelheim Vietnam also committed to accompany FPT Long Chau to conduct training to improve direct and online consulting skills, related to cardiovascular - kidney - metabolic diseases for medical staff and pharmacists working at the pharmacy chain according to the criteria: right disease, right medicine, right dose, right method.
Source: https://dantri.com.vn/suc-khoe/long-chau-hop-tac-boehringer-ingelheim-tam-soat-benh-than-man-mien-phi-cho-nguoi-dan-20250608183700291.htm
Comment (0)